Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Completed · Phase 4

Conditions studied: Plaque Psoriasis

In brief

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Key facts

Study ID

NCT00437255

Run by

Galderma R&D

People needed

122

Starts

2006-08-01

Expected to finish

2007-06-01

Last updated by the study team

2022-07-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe psoriasis involving 3-20% of the body surface area

You may not qualify if…

• Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
• Subjects having psoriasis that involves the scalp, face, or groin

Where it is running

• Minnesota Clinical Study Center — Fridley, Minnesota, United States
• DermResearch, Inc. — Austin, Texas, United States
• J & S Studies, Inc. — Bryan, Texas, United States
• Baylor Research Institute — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.